Fibrinogen has chaperone-like activity

Biochemical and Biophysical Research Communications

Volumn 378, Issue 3, 2009, Pages 662-667

  Tang, Huadong ^a   Fu, Yan ^a   Cui, Yujie ^a   He, Yingbo ^a   Zeng, Xing ^a   Ploplis, Victoria A ^b   Castellino, Francis J ^b   Luo, Yongzhang ^a  

^a TSINGHUA UNIVERSITY   (China)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Aggregation; Chaperone; Extracellular; Fibril formation; Fibrinogen; Misfolding

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHAPERONE; CITRATE SYNTHASE; FIBRINOGEN; LUCIFERASE; PRION PROTEIN; PROTEIN SUP53; UNCLASSIFIED DRUG;

ARTICLE; CELL LYSATE; FIBER; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; RETICULOCYTE; TEMPERATURE STRESS; THERMOSTABILITY;

MUS; ORYCTOLAGUS CUNICULUS;

EID: 57749192234     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.11.112     Document Type: Article

References (42)

1. Horwich A. Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J. Clin. Invest. 110 (2002) 1221-1232
2. Dobson C.M. Principles of protein folding, misfolding and aggregation. Semin. Cell Dev. Biol. 15 (2004) 3-16
3. Bukau B., Weissman J., and Horwich A. Molecular chaperones and protein quality control. Cell 125 (2006) 443-451
4. Frydman J. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu. Rev. Biochem. 70 (2001) 603-647
5. Yerbury J.J., Stewart E., Wyatt A., and Wilson M.R. Quality control of protein folding in extracellular space. EMBO Rep. 6 (2005) 1131-1136
6. Humphreys D., Carver J., Easterbrook-Smith S.B., and Wilson M.R. Clusterin has chaperone-like activity similar to that of small heat-shock proteins. J. Biol. Chem. 274 (1999) 6875-6881
7. Kanekiyo T., et al. Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid. Proc. Natl. Acad. Sci. USA 104 (2007) 6412-6417
8. Coke A.R., Purvis A., Baker D., Pepys M.B., and Wood S.P. Molecular chaperone properties of serum amyloid P component. FEBS Lett. 473 (2000) 199-202
9. Putnam F.W. The Plasma Proteins. second ed. (1975), Academic Press, New York
10. Doolittle R.F. Fibrinogen and fibrin. Annu. Rev. Biochem. 53 (1984) 195-229
11. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340 (1999) 448-454
12. Wilhelmsen L., et al. Fibrinogen as risk factor for stroke and myocardial infarction. N. Engl. J. Med. 311 (1984) 501-505
13. Fowkes F.G., Lee A.J., Lowe G.D., Riemersma R.A., and Housley E. Inter-relationships of plasma fibrinogen, low density lipoprotein cholesterol, cigarette smoking and the prevalence of cardiovascular disease. J. Cardiovasc. Risk 3 (1996) 307-311
14. Buchner J., Grallert H., and Jakob U. Analysis of chaperone function using citrate synthase as nonnative substrate protein. Methods Enzymol. 290 (1998) 323-338
15. Lee G.J., Roseman A.M., Saibil H.R., and Vierling E. A small heat shock protein stably binds heat-denatured model substrates and can maintain a substrate in a folding-competent state. EMBO J. 16 (1997) 659-671
16. Glover J.R., and Lindquist S. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 94 (1998) 73-82
17. Glover J.R., Kowal A.S., Schirmer E.C., Patino M.M., Liu J.J., and Lindquist S. Self-seeded fibers formed by Sup35, the protein determinant of [PSI+], a heritable prion-like factor of S. cerevisiae. Cell 89 (1997) 811-819
18. Ploplis V.A., et al. A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am. J. Pathol. 157 (2000) 703-708
19. Chien P., DePace A.H., Collins S.R., and Weissman J.S. Generation of prion transmission barriers by mutational control of amyloid conformations. Nature 424 (2003) 948-951
20. Hartl F.U. Molecular chaperones in cellular protein folding. Nature 381 (1996) 571-580
21. Frydman J., Nimmesgern E., Ohtsuka K., and Hartl F.U. Folding of nascent polypeptide in a high molecular weight complex with molecular chaperones. Nature 370 (1994) 111-117
22. Dobson C.M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24 (1999) 329-332
23. Barral J.M., Broadley S.A., Schaffar G., and Hartl F.U. Roles of molecular chaperones in protein misfolding diseases. Semin. Cell Dev. Biol. 15 (2004) 17-29
24. Kumita J.R., Poon S., Caddy G.L., Hagan C.L., Dumoulin M., Yerbury J.J., Stewart E.M., Robinson C.V., Wilson M.R., and Dobson C.M. The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species. J. Mol. Biol. 369 (2007) 157-167
25. Lucas M.A., Fretto L.J., and McKee P.A. The binding of human plasminogen to fibrin and fibrinogen. J. Biol. Chem. 258 (1983) 4249-4256
26. Booth D.R., Sunde M., Bellotti V., Robinson C.V., Hutchinson W.L., Fraser P.E., et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385 (1997) 787-793
27. Ursini F., Davies K.J.A., Maiorino M., Parasassi T., and Sevanian A. Atherosclerosis: another protein misfolding disease?. Trends Mol. Med. 8 (2002) 370-374
28. Casserly I., and Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol and misfolded proteins. Lancet 363 (2004) 1139-1146
29. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., and Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002) 507-511
30. Fowler D.M., Koulov A.V., Balch W.E., and Kelly J.W. Functional amyloid-from bacteria to humans. Trends Biochem. Sci. 32 (2007) 217-224
31. Shibayama Y., et al. Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clin. Immunol. 90 (1999) 89-99
32. Kranenburg O., et al. Tissue-type plasminogen activator is a multiligand cross-beta structure receptor. Curr. Biol. 12 (2002) 1833-1839
33. Benson M.D., Liepnieks J., Uemichi T., Wheeler G., and Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat. Genet. 3 (1993) 252-255
34. Uemichi T., Liepnieks J.J., and Benson M.D. Hereditary renal amyloidosis with a novel variant fibrinogen. J. Clin. Invest. 93 (1994) 731-736
35. Uemichi T., et al. A frame shift mutation in the fibrinogen Aα chain gene in a kindred with renal amyloidosis. Blood 87 (1996) 4197-4203
36. Fischer M.B., Roeckl C., Parizek P., and Schwarz H.P. Binding of disease-associated prion protein to plasminogen. Nature 408 (2000) 479-483
37. Iwaki T., Sandoval-Cooper M.J., Brechmann M., Ploplis V.A., and Castellino F.J. Afibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice. Blood 107 (2006) 3883-3891
38. Barazzoni R.B., et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J. Clin. Endocrinol. 85 (2000) 3121-3125
39. Adler A.I., Gunn E., Haworth C.S., and Bilton D. Characteristics of adults with and without cystic fibrosis-related diabetes. Diabet. Med. 24 (2007) 1143-1148
40. Hoppener J.W.M., Ahpen B., and Lips C.J.M. Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med. 343 (2008) 411-419
41. Oijen M.V., Witteman J.C., Hofman A., Koudstaal P.J., and Breteler M.M.B. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36 (2005) 2637-2641
42. Herrick S., Blanc-Brude O., Gray A., and Laurent G. Fibrinogen. Int. J. Biochem. Cell Biol. 31 (1999) 741-746